Antitumor Activity of Compound 1 in a RT-112 FGFR3-Driven Human Cancer Cell Line-Derived Xenograft Model






FIG. 1A



FGFR = fibroblast growth factor receptor; n = number; TGI = tumor growth inhibition; TV = tumor volume

FIG. 1B

Antitumor Activity of Compound 1 in a RT-112 FGFR3-Driven Human Cancer Cell Line-Derived Xenograft Model



FGFR = fibroblast growth factor receptor; n = number; TGI = tumor growth inhibition; TV = tumor volume

FIG. 1C

Antitumor Activity of Compound 1 in a FGFR2-Driven Human Cancer Cell Line-Derived Xenograft Model





FIG. 2A




FGFR = fibroblast growth factor receptor; n = number; TGI = tumor growth inhibition; TV = tumor volume

* Denotes animal with -1% TGI.

FIG. 2B


Antitumor Activity of Compound 1 in a FGFR2-Driven Human Cancer Cell Line-Derived Xenograft Model



FGFR = fibroblast growth factor receptor; n = number; TGI = tumor growth inhibition; TV = tumor volume

* Denotes animal with -1% TGI.

FIG. 2C



$$* \text{ DLT rate} = \frac{\text{Total number of participants who experienced DLT at the current dose}}{\text{Total number of evaluable participants treated at the current dose}}$$

FIG. 3